FDA greenlights 3D-printed cervical spacer system

Dave Pearson | | Health Exec | Economics
neck_pain.jpg
Photo by Kindel Media via Pexels

An established company in the spinal device market has added a 3D-printed vertebral spacer to its line of FDA-cleared products.

Lewisville, Texas-based Orthofix Medical says its latest offering allows neck bone to grow into and through the spacer, helping the patient’s cervical vertebrae to fuse following the spacer’s surgical insertion as a lasting therapy for herniated or degenerative discs.

Called the Construx Mini Ti (for titanium) spacer system, the newly approved technology follows several similar products in Orthofix’s line to win FDA’s OK.

The company says the Mini Ti features 3D-printed porous titanium with macro, micro and nanoscale surface features.

Full announcement here.

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

Walgreens confirms $10B sale to PE, as part of $24B transaction
5 ways AI can help make healthcare more affordable for everyone
More than 1,000 hospitals earn $700M opioid crisis judgment
Building a successful CCTA program: Physicians and healthcare executives to share advice
VA planning 83,000 layoffs as part of restructuring
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.